Betta Pharmaceuticals Co., Ltd.

Xiaofeng Xu

Lieming Ding

Jiabing Wang

Yan Xu

Xiangyong Liu

The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds.

Compound functioning as bromodomain protein inhibitor, and composition

The invention relates to a bromodomain inhibitor. The invention also provides compositions and formulations comprising such compounds, and methods of using and preparing such compounds. 

An azatricyclic compound (as represented by Formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases are provided. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like. 

Growing community of inventors

Beijing, China

Xiaofeng Xu